Samsung Biologics, a renowned contract development and manufacturing organization (CDMO), has recently forged a series of manufacturing agreements with a pharmaceutical company based in Europe.
These newly revealed contracts, valued at over $668 million in total, are set to extend through the end of December 2031. These latest arrangements push the company’s total contract value for the current year past the $4 billion mark.
“We are thrilled to deepen our collaboration with the European pharmaceutical firm, enhancing our mutual commitment to supplying top-notch biopharmaceuticals to patients,” expressed John Rim, president and CEO of Samsung Biologics. “As we broaden our strategic alliances with clients globally, we continuously invest in advancing our capabilities and manufacturing methodologies. Our mission is to offer superior quality services at each stage and strengthen our trusted collaborations.”
Samsung Biologics has actively adapted to the ever-changing requirements of its clients through a succession of paramount agreements this year, cementing its clientele base across the US, Asia, and Europe. The company collaborates with 17 out of the world’s top 20 pharmaceutical firms and is extending contracts with existing clients to facilitate their progress with pioneering treatments.
The company plans to introduce antibody-drug conjugate (ADC) services into its offerings, with the construction of a dedicated facility expected to conclude by year-end. Samsung Biologics will provide an array of services, including ADC process development and conjugation, drawing on its in-depth knowledge of biologics and proficiency in antibody production and engineering. Additionally, Samsung Biologics will unveil Bio Campus II next year, with Plant 5 slated to start operations in April 2025.
Samsung Biologics remains an all-encompassing, end-to-end CDMO service provider offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish, along with laboratory testing services throughout the biopharmaceutical product lifecycle.